Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (331-340 of 427) with videos related to

Pageof 43
Sort By:
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Cell Death & Disease|November 18, 2022
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myelomaOdai Darawshi, Barbara Muz, Shiri Gershon Naamat, et al.
Cancer Research|September 4, 2012
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivoMarc S Raab, Iris Breitkreutz, Simon Anderhub, et al.
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Annals of Internal Medicine|September 13, 2013
A prospective assessment defining the limitations of thyroid nodule pathologic evaluationEdmund S Cibas, Zubair W Baloch, Giovanni Fellegara, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Blood|July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesK Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Blood Advances|August 1, 2022
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MMKatharina Kriegsmann, Calin Manta, Ricarda Schwab, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Pageof 43

Showing results (331-340 of 427) with videos related to

Sort By:
Pageof 43
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Cell Death & Disease|November 18, 2022
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myelomaOdai Darawshi, Barbara Muz, Shiri Gershon Naamat, et al.
Cancer Research|September 4, 2012
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivoMarc S Raab, Iris Breitkreutz, Simon Anderhub, et al.
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Annals of Internal Medicine|September 13, 2013
A prospective assessment defining the limitations of thyroid nodule pathologic evaluationEdmund S Cibas, Zubair W Baloch, Giovanni Fellegara, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Blood|July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesK Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Blood Advances|August 1, 2022
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MMKatharina Kriegsmann, Calin Manta, Ricarda Schwab, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Pageof 43